Logo image of BGNE

BEIGENE LTD-ADR (BGNE) Stock Fundamental Analysis

NASDAQ:BGNE - Nasdaq - US07725L1026 - ADR - Currency: USD

184.71  +0.9 (+0.49%)

After market: 184.71 0 (0%)

Fundamental Rating

3

Overall BGNE gets a fundamental rating of 3 out of 10. We evaluated BGNE against 558 industry peers in the Biotechnology industry. BGNE has a bad profitability rating. Also its financial health evaluation is rather negative. BGNE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

BGNE had negative earnings in the past year.
BGNE had a negative operating cash flow in the past year.
BGNE had negative earnings in each of the past 5 years.
BGNE had a negative operating cash flow in each of the past 5 years.
BGNE Yearly Net Income VS EBIT VS OCF VS FCFBGNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2B -4B -6B -8B -10B

1.2 Ratios

BGNE has a Return On Assets of -15.97%. This is amongst the best in the industry. BGNE outperforms 81.63% of its industry peers.
BGNE has a better Return On Equity (-26.99%) than 80.74% of its industry peers.
Industry RankSector Rank
ROA -15.97%
ROE -26.99%
ROIC N/A
ROA(3y)-21.61%
ROA(5y)-31.52%
ROE(3y)-32.05%
ROE(5y)-48.63%
ROIC(3y)N/A
ROIC(5y)N/A
BGNE Yearly ROA, ROE, ROICBGNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of BGNE (83.13%) is better than 87.63% of its industry peers.
In the last couple of years the Gross Margin of BGNE has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BGNE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.09%
GM growth 5Y-0.25%
BGNE Yearly Profit, Operating, Gross MarginsBGNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

BGNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BGNE has more shares outstanding
BGNE has more shares outstanding than it did 5 years ago.
BGNE has a worse debt/assets ratio than last year.
BGNE Yearly Shares OutstandingBGNE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
BGNE Yearly Total Debt VS Total AssetsBGNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B 50B

2.2 Solvency

An Altman-Z score of 3.53 indicates that BGNE is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.53, BGNE is doing good in the industry, outperforming 77.03% of the companies in the same industry.
BGNE has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
BGNE's Debt to Equity ratio of 0.31 is on the low side compared to the rest of the industry. BGNE is outperformed by 71.02% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 3.53
ROIC/WACCN/A
WACC10.79%
BGNE Yearly LT Debt VS Equity VS FCFBGNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10B -10B 20B 30B

2.3 Liquidity

A Current Ratio of 1.94 indicates that BGNE should not have too much problems paying its short term obligations.
BGNE has a worse Current ratio (1.94) than 76.68% of its industry peers.
BGNE has a Quick Ratio of 1.72. This is a normal value and indicates that BGNE is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.72, BGNE is not doing good in the industry: 79.15% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.72
BGNE Yearly Current Assets VS Current LiabilitesBGNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B

More info and screens

7

3. Growth

3.1 Past

The earnings per share for BGNE have decreased strongly by -457.37% in the last year.
BGNE shows a strong growth in Revenue. In the last year, the Revenue has grown by 52.08%.
BGNE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 67.79% yearly.
EPS 1Y (TTM)-457.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-159.34%
Revenue 1Y (TTM)52.08%
Revenue growth 3Y101.8%
Revenue growth 5Y67.79%
Sales Q2Q%26.79%

3.2 Future

BGNE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 77.27% yearly.
The Revenue is expected to grow by 25.88% on average over the next years. This is a very strong growth
EPS Next Y35.87%
EPS Next 2Y36.2%
EPS Next 3Y34.59%
EPS Next 5Y77.27%
Revenue Next Year52.03%
Revenue Next 2Y37.72%
Revenue Next 3Y30.68%
Revenue Next 5Y25.88%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BGNE Yearly Revenue VS EstimatesBGNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B
BGNE Yearly EPS VS EstimatesBGNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 500 1K 1.5K 2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BGNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BGNE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGNE Price Earnings VS Forward Price EarningsBGNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGNE Per share dataBGNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

BGNE's earnings are expected to grow with 34.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.2%
EPS Next 3Y34.59%

More info and screens

0

5. Dividend

5.1 Amount

BGNE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEIGENE LTD-ADR

NASDAQ:BGNE (12/31/2024, 8:10:09 PM)

After market: 184.71 0 (0%)

184.71

+0.9 (+0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners28.08%
Inst Owner Change-1.52%
Ins OwnersN/A
Ins Owner Change12.42%
Market Cap19.67B
Analysts81.82
Price Target185.96 (0.68%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.1
Dividend Growth(5Y)N/A
DP-2.03%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-414.4%
Min EPS beat(2)-805.99%
Max EPS beat(2)-22.81%
EPS beat(4)0
Avg EPS beat(4)-490.89%
Min EPS beat(4)-999.2%
Max EPS beat(4)-22.81%
EPS beat(8)1
Avg EPS beat(8)-245.79%
EPS beat(12)2
Avg EPS beat(12)-169.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.14%
Min Revenue beat(2)0.26%
Max Revenue beat(2)28.03%
Revenue beat(4)4
Avg Revenue beat(4)14.86%
Min Revenue beat(4)0.26%
Max Revenue beat(4)28.03%
Revenue beat(8)8
Avg Revenue beat(8)17.74%
Revenue beat(12)11
Avg Revenue beat(12)13.77%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.41%
PT rev (3m)-12.24%
EPS NQ rev (1m)-0.26%
EPS NQ rev (3m)55.77%
EPS NY rev (1m)0.26%
EPS NY rev (3m)11.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)30.05%
Revenue NY rev (1m)0.71%
Revenue NY rev (3m)6.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.09
P/FCF N/A
P/OCF N/A
P/B 5.96
P/tB 6.18
EV/EBITDA N/A
EPS(TTM)-49.45
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-10.5
FCFYN/A
OCF(TTM)-5.42
OCFYN/A
SpS30.34
BVpS30.97
TBVpS29.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.97%
ROE -26.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.13%
FCFM N/A
ROA(3y)-21.61%
ROA(5y)-31.52%
ROE(3y)-32.05%
ROE(5y)-48.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.09%
GM growth 5Y-0.25%
F-Score4
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 16.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.72
Altman-Z 3.53
F-Score4
WACC10.79%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.9%
Cap/Sales(5y)29.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-457.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-159.34%
EPS Next Y35.87%
EPS Next 2Y36.2%
EPS Next 3Y34.59%
EPS Next 5Y77.27%
Revenue 1Y (TTM)52.08%
Revenue growth 3Y101.8%
Revenue growth 5Y67.79%
Sales Q2Q%26.79%
Revenue Next Year52.03%
Revenue Next 2Y37.72%
Revenue Next 3Y30.68%
Revenue Next 5Y25.88%
EBIT growth 1Y29.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.98%
EBIT Next 3Y32.29%
EBIT Next 5Y33.22%
FCF growth 1Y33.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.76%
OCF growth 3YN/A
OCF growth 5YN/A